SINOVAC Biopharmaceutical's Partner Receives UK Marketing Authorization for Nab-Paclitaxel (Apexelsin®)

Zhitong Finance APP reported that Kexing Biopharm (688136.SH) announced its partner, Haichang Biotech, recently received the marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the company's imported product, Albumin-bound Paclitaxel for Injection (Apexelsin®, hereinafter referred to as "Albumin Paclitaxel"). Indications for this drug include the treatment of metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer, among other cancers.

Injectable Albumin-Bound Paclitaxel Offers Clinical Advantages Over Conventional Paclitaxel Injection and Paclitaxel Liposome, With Improved Safety and Patient Compliance, Gaining High Clinical Recognition and Demonstrating Indispensable Value in Cancer Treatment. The Company is Actively Expanding its Marketing Channels in the European Market. The Albumin-Bound Paclitaxel Introduced by the Company Has Received Marketing Authorization in the EU. The Recent Approval of Albumin-Bound Paclitaxel in the UK Will Further Accelerate the Company’s Overseas Market Expansion, Enhance Its Market Competitiveness, and Positively Impact the Company’s Future Operations.